Research Progress on Immunotherapy for Thyroid Carcinoma

Transcript

1 1 2 2 ( ; ) : (PTC) (FTC) (MTC) (ATC)4 PTC 85% : ; ; :R736.1 :A : (2018) doi: /j.issn a008 Research Progress on Immunotherapy for Thyroid Carcinoma QIAN Yang-yang 1 GE Ming-hua 2 PAN Zong-fu 2 (1. Wenzhou Medical UniversityWenzhou China;2. Zhejiang Cancer HospitalHangzhou China) Abstract:Thyroid cancer is the most common malignant tumor in the endocrine system. There are 4 pathological types of thyroid cancer:papillary carcinoma (PTC)follicular carcinoma (FTC) medullary carcinoma(mtc)undifferentiated carcinoma(atc); and PTC is the most common type accounting for about 85%. The incidence of thyroid cancer is increasing in recent years. Surgery endocrine therapy and radiotherapy are the three therapeutic modalities for thyroid cancerand the overall curative effect is favorable. But some thyroid cancerssuch as iodide-resistant metastatic differentiated thyroid cancerpoorly differentiated carcinomaundifferentiated carcinoma have poor prognosis and lack of effective treatment methods. Immunotherapy is a promisingnovel therapeutic strategy for malignant tumors; it would be a new solution for the treatment of some types of thyroid carcinoma. Currentlythe methods of immunotherapy used for thyroid cancer include tumor vaccine therapyimmune checkpoint inhibitor therapyadoptive immunotherapymonoclonal antibody therapy and immunoregulatory cell-targeted therapy. Key words:thyroid carcinoma;immunotherapy;endocrine system 5 90% [1] : ; : : ( ); (WKJ-ZJ-1605); (2015C03027) : gemingh@163.com 359

2 1.2 : (oncolytic viruseov) [1] OV 1 OV [8] GM-CSF [9] Passaro [10] dl [2] -8 -γ (dendritic celldc) OV [1] DC T [2] DC DC DC ( CD4 + T ) ( ) DC T (Treg) Treg [3] (MTC) T -4 (cytotoxic T- [4] DC lymphocyte antigen 4CTLA-4) -1 Alamino [5] T 3 (programmed death 1PD-1) DC [11] DC CTLA-4 PD CTLA-4 GVAX DC CD8 + T CTLA-4 [12] (GM-CSF) B7 T [6] Alessandra Schey- Cherng [1] GVAX CTLA-4 (thyroglobulin antibodietgab) OV T 2 CTLA-4 CD152 CD4 + CTLA-4 [13] Ipilimuma 60% MTC (United States Food and DC Drug AdministrationFDA) [7] DC CTLA-4 PD-1 360

3 [14] Tremelimumab CTLA-4 Ipilimumab [15] T CTLA PD-1/PD-L1 PD-1 CD28 (chimeric antigen receptor T B CAR) T T -1(programmed death ligand 1PD-L1) PD-L2 PD-1 PD-L1 T T T CTLA-4 [16] PD-L1 T [17] [5] T PD-1/ PD-L1 T TERT CAR-T PD-1/PD-L1 [22] TERT [18] Soomin [19] CAR-T 407 PD-L1 (PTC) (FTC) (ATC) 6.1% 7.6% 22.2%PD-L1 4 80% PD-L1 [21] (CAR-T ) T Nivolumab Pembrolizumab FDA PD-1 Nivolumab NK BRAF V600E Atezolizumab IgG4 PD-L1 [23] FDA CD20 [24] Atezolizumab 2(Her-2) PD-L1 Atezolizumab [25] [20] (TSHR) PD-1/ PD-L1 5 3 (tumor-associated macrophagestam) T 361

4 (DSV-PTC) 2 TAM [26] 2 TAM [1] Mould RCVan JVAuyeung Aet al. Immune response in the thyroid cancer microenvironment:making immunotherapy a possible mission [J]. Endocr Relat Cancer [27] 2 TAM Carlumab CC 2 (12):T311-T329. [2] Sabado RLBhardwaj N. Dendritic cell immunotherapy[j]. Ann N Y Acad Sci (1): [28] / [3] Bachleitnerhofmann TFriedl JHassler Met al. Pilot trial (HRG) IL-12 of autologous dendritic cells loaded with tumor lysate (s) [29] TAM M1 from allogeneic tumor cell lines in patients with metastatic TAM medullary thyroid carcinoma [J]. Oncol Rep200921(6): ATC [4] Kuwabara KNishishita TMorishita Met al. Results of a phase clinical study using dendritic cell vaccinations 6 T for thyroid cancer[j]. Thyroid200717(1): [5] Alamino VAMascanfroni IDMontesinos MMet al. Antitumor responses stimulated by dendritic cells are im- T (regulatory T cellstregs) proved by triiodothyronine binding to the thyroid hormone Tregs PTC receptor β[j]. Cancer Res201575(7): [6] De RAde Gruijl TDUram JNet al. Development of thyroglobulin antibodies after GVAX immunotherapy is asso- [30] Tregs ciated with prolonged survival [J]. Int J Cancer Treg Treg (1): [7] Stift ASachet MYagubian Ret al. Dendritic cell vaccination in medullary thyroid carcinoma [J]. Clin Cancer CD25 IL-2 [31] (ONTAK) Tregs Treg CD25 Res200410(9): T [8] Chiocca EARabkin SD. Oncolytic viruses and their application to cancer immunotherapy[j]. Cancer Immunol Res CD25 CD25 Treg T 20142(4): Treg [9] Kaufman HLKohlhapp FJZloza A. Oncolytic viruses:a [32] new class of immunotherapy drugs [J]. Nat Rev Drug Discov201514(9): [10] Passaro CAbagnale ALibertini Set al. Ionizing radia- 7 : tion enhances dl mediated cell death of anaplastic thyroid carcinoma cells[j]. Endocr Relat Cancer (5): [11] Zou W. Regulatory T cellstumour immunity and immunotherapy[j]. Nat Rev Immunol20066(4): [12] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[j]. Nat Rev Cancer201212(4): [13] Amin ALawson DHSalama AKet al. Phase study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma [J] Immunother Cancer20164:

5 [14] Topalian SLHodi FSB rahmer JRet al.safetyactivity and immune correlates of anti-pd-1 antiody in cancer[j]. N Engl J Med (26): [15] Kirkwood JMLorigan PHersey Pet al. Phase trial of tremelimumab(cp ) in patients with advanced refractory or relapsed melanoma [J]. Clin Cancer Res (16): [16] Francisco LMSage PTSharpe AH. The PD-1 pathway in tolerance and autoimmunity [J]. Immunol Rev (1): [17] Fourcade JSun ZPagliano Oet al. CD8 (+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1 [J]. Cancer Res (4): [18] Kollipara RSchneider BRadovich Met al. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer[j]. Oncologist20176(5): [19] Ahn SKim THKim SWet al. Comprehensive screening for PD-L1 expression in thyroid cancer [J]. Endocr Relat Cancer201724(2): [20] Rittmeyer ABarlesi FWaterkamp Det al. Atezolizumab versus docetaxel in patients with previously treated nonsmall-cell lung cancer(oak):a phase 3open-labelmulticentre randomised controlled trial [J]. Lancet (10066): [21] Rosenberg SARestifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer [J]. Science (6230): [22] Sandri SDe SFLamolinara Aet al. Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T- cell therapy[j]. Oncotarget20178(50): [23] Weiner LMMurray JCShuptrine CW. Antibody-based immunotherapy of cancer[j]. Cell (6): [24] Iagaru AMittra ESGanjoo Ket al. 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of lowgrade refractory/relapsed non-hodgkin lymphoma [J]. Mol Imaging Biol201012(2): [25] Elliott DDSherman SIBusaidy NLet al. Growth factor receptors expression in anaplastic thyroid carcinoma:potential markers for therapeutic stratification [J]. Hum Pathol200839(1): [26] Chang WCChen JYLee CHet al. Expression of decoy receptor 3 in diffuse sclerosing variant of papillary thyroid carcinoma:correlation with M2 macrophage differentiation and lymphatic invasion[j]. Thyroid201323(6): [27] Guth AMHafeman SDElmslie REet al. Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma[j]. Vet Comp Oncol (4):296. [28] Qian BZLi JZhang Het al. CCL2 recruit s inflammatory monocytes to facilitate breast-tumour metastasis [J]. Nature (7355): [29] Rolny CMazzone MTugues Set al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF[J]. Cancer Cell201119(1): [30] Gogali FPaterakis GRassidakis GZet al. Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid[j]. J Clin Endocrinol Metab201297(5): [31] de Vries IJCastelli CHuygens Cet al. Frequency of circulating tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents [J]. Clin Cancer Res (4): [32] Balachandran VPCavnar MJShan Zet al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido [J]. Nat Med (9):